Drug Profile
Lamivudine/nevirapine/zidovudine
Alternative Names: Lamivudine/zidovudine/nevirapine; Nevirapine/lamivudine/zidovudine; Nevirapine/zidovudine/lamivudine; Zidovudine/lamivudine/nevirapine; Zidovudine/nevirapine/lamivudineLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Duquesne University
- Developer Elim Pediatric Pharmaceuticals
- Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Azides; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Nucleosides; Pyridines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in Nigeria (PO, Granules)
- 28 Apr 2018 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in Nigeria (PO, Tablet)
- 01 Jun 2013 Lamivudine/nevirapine/zidovudine may be available for partnering. www.elimpedpharma.com